|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cooper GM: The eukaryotic cell cycle. The
cell: A Molecular Approach. 2nd edition. Cooper GM: ASM Press;
Washington, DC: 2000
|
|
3
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen T, Stephens PA, Middleton FK and
Curtin NJ: Targeting the S and G2 checkpoint to treat cancer. Drug
Discov Today. 17:194–202. 2012. View Article : Google Scholar
|
|
6
|
Marzo I and Naval J: Antimitotic drugs in
cancer chemotherapy: Promises and pitfalls. Biochem Pharmacol.
86:703–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dickson MA: Molecular pathways: CDK4
inhibitors for cancer therapy. Clin Cancer Res. 20:3379–3383. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lyon J, Robinson C and Watson R: The role
of Myb proteins in normal and neoplastic cell proliferation. Crit
Rev Oncog. 5:373–388. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanaka Y, Patestos NP, Maekawa T and Ishii
S: B-myb is required for inner cell mass formation at an early
stage of development. J Biol Chem. 274:28067–28070. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sala A: B-MYB, a transcription factor
implicated in regulating cell cycle, apoptosis and cancer. Eur J
Cancer. 41:2479–2484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mowla SN, Lam EWF and Jat PS: Cellular
senescence and aging: The role of B-MYB. Aging Cell. 13:773–779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Down CF, Millour J, Lam EW and Watson RJ:
Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb.
Biochim Biophys Acta. 1819:855–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu N, Lucibello FC, Zwicker J, Engeland K
and Müller R: Cell cycle-regulated repression of B-myb
transcription: Cooperation of an E2F site with a contiguous
corepressor element. Nucleic Acids Res. 24:2905–2910. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang JS and Lai EC: Alternative miRNA
biogenesis pathways and the interpretation of core miRNA pathway
mutants. Mol Cell. 43:892–903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA Deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang LH and He XH: Macro-management of
microRNAs in cell cycle progression of tumor cells and its
implications in anti-cancer therapy. Acta Pharmacol Sin.
32:1311–1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martinez I, Cazalla D, Almstead LL, Steitz
JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during
cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011.
View Article : Google Scholar :
|
|
20
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive miR-34a induces senescence-like
growth arrest through modulation of the E2F pathway in human colon
cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeon YJ, Jung SN, Yun J, Lee CW, Choi J,
Lee YJ, Han DC and Kwon BM: Ginkgetin inhibits the growth of DU-145
prostate cancer cells through inhibition of signal transducer and
activator of transcription 3 activity. Cancer Sci. 106:413–420.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You OH and Kim SH, Kim B, Sohn EJ, Lee HJ,
Shim BS, Yun M, Kwon BM and Kim SH: Ginkgetin induces apoptosis via
activation of caspase and inhibition of survival genes in PC-3
prostate cancer cells. Bioorg Med Chem Lett. 23:2692–2695. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang SS, Kim JS, Kwak WJ and Kim KH:
Flavonoids from the leaves of Ginkgo biloba. Korean J Pharmacogn.
21:111–120. 1990.
|
|
24
|
Ye ZN, Yu MY, Kong LM, Wang WH, Yang YF,
Liu JQ, Qiu MH and Li Y: Biflavone ginkgetin, a novel Wnt
inhibitor, suppresses the growth of medulloblastoma. Nat Prod
Bioprospect. 5:91–97. 2015. View Article : Google Scholar :
|
|
25
|
Merrill GF: Cell synchronization. Methods
Cell Biol. 57:229–249. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schorl C and Sedivy JM: Analysis of cell
cycle phases and progression in cultured mammalian cells. Methods.
41:143–150. 2007. View Article : Google Scholar :
|
|
27
|
Wei Y, Mizzen CA, Cook RG, Gorovsky MA and
Allis CD: Phosphorylation of histone H3 at serine 10 is correlated
with chromosome condensation during mitosis and meiosis in
Tetrahymena. Proc Natl Acad Sci USA. 95:7480–7484. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pilkinton M, Sandoval R, Song J, Ness SA
and Colamonici OR: Mip/LIN-9 regulates the expression of B-Myb and
the induction of cyclin A, cyclin B, and CDK1. J Biol Chem.
282:168–175. 2007. View Article : Google Scholar
|
|
29
|
Knight AS, Notaridou M and Watson RJ: A
Lin-9 complex is recruited by B-Myb to activate transcription of
G2/M genes in undifferentiated embryonal carcinoma cells. Oncogene.
28:1737–1747. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martinez I, Cazalla D, Almstead LL, Steitz
JA and DiMaio D: MiR-29 and miR-30 regulate B-Myb expression uring
cellular senescence. Proc Natl Acad Sci USA. 92:9363–9367.
2011.
|
|
31
|
Zauli G, Voltan R, di Iasio MG, Bosco R,
Melloni E, Sana ME and Secchiero P: miR-34a induces the
downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
Clin Cancer Res. 17:2712–2724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Del Rio D, Rodriguez-Mateos A, Spencer JP,
Tognolini M, Borges G and Crozier A: Dietary (poly)phenolics in
human health: Structures, bioavailability, and evidence of
protective effects against chronic diseases. Antioxid Redox Signal.
18:1818–1892. 2013. View Article : Google Scholar :
|
|
33
|
Lu MF, Xiao ZT and Zhang HY: Where do
health benefits of flavonoids come from? Insights from flavonoid
targets and their evolutionary history. Biochem Biophys Res Commun.
434:701–704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh RP and Agarwal R: Natural flavonoids
targeting deregulated cell cycle progression in cancer cells. Curr
Drug Targets. 7:345–354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liberio MS, Sadowski MC, Davis RA,
Rockstroh A, Vasireddy R, Lehman ML and Nelson CC: The ascidian
natural product eusynstyelamide B is a novel topoisomerase II
poison that induces DNA damage and growth arrest in prostate and
breast cancer cells. Oncotarget. 6:43944–43963. 2015. View Article : Google Scholar
|
|
36
|
Nakata Y, Shetzline S, Sakashita C, Kalota
A, Rallapalli R, Rudnick SI, Zhang Y, Emerson SG and Gewirtz AM:
c-Myb contributes to G2/M cell cycle transition in human
hematopoietic cells by direct regulation of cyclin B1 expression.
Mol Cell Biol. 27:2048–2058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Agostini M and Knight RA: miR-34: From
bench to bedside. Oncotarget. 5:872–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wong KY, Yu L and Chim CS: DNA methylation
of tumor suppressor miRNA genes: A lesson from the miR-34 family.
Epigenomics. 3:83–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peng X, Chang H, Gu Y, Chen J, Yi L, Xie
Q, Zhu J, Zhang Q and Mi M: 3,6-Dihydroxyflavone suppresses breast
carcinogenesis by epigenetically regulating miR-34a and miR-21.
Cancer Prev Res (Phila). 8:509–517. 2015. View Article : Google Scholar
|
|
41
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
